DBX4:F:F-Xtrackers - MSCI EM Europe Middle East & Africa Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 30.085

Change

0.00 (0.00)%

Market Cap

N/A

Volume

17.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-2.80 (-0.56%)

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.17 (-0.38%)

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.34 (-0.68%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

-6.58 (-7.02%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.60 (+0.30%)

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 41.48B
0ZC:F Zscaler Inc

+6.24 (+3.85%)

USD 37.92B
BSND:F Danone SA

-0.60 (-4.17%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-7.02 (-5.87%)

USD 24.77B

ETFs Containing DBX4:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.10% 36% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.10% 37% F 48% F
Trailing 12 Months  
Capital Gain 7.60% 83% B 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.60% 80% B- 62% D
Trailing 5 Years  
Capital Gain 53.54% 54% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.54% 54% F 40% F
Average Annual (5 Year Horizon)  
Capital Gain 7.87% 60% D- 60% D-
Dividend Return 7.87% 58% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.68% 57% F 87% B+
Risk Adjusted Return 67.43% 67% D+ 76% C+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike